

Applicants : Ron S. Israeli, et al.
U.S. Serial No.: Not Yet Known
Filed : March 17, 1995
Page 2

- 45. (Amended) An immunoassay for measuring the amount of a mammalian prostate-specific membrane antigen in a biological sample comprising steps of: a) contacting the biological sample with at least one ligand of claim 23 [or 27] to form a complex with said ligand and the mammalian prostate-specific membrane antigen, and b) measuring the amount of the mammalian prostate-specific membrane antigen in said biological sample by measuring the amount of said complex.--
- 49. (Amended) A method of suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells, comprising introducing a DNA molecule encoding a prostate specific membrane antigen of claim 1 operatively linked to a 5' regulatory element into a tumor cell of a subject, in a way that expression of the prostate specific membrane antigen is under the control of the regulatory element, thereby suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells.--
- 74. (Amended) A [prostate tumor] cell, comprising a DNA molecule of claim [2] 1 under the control of a prostate specific membrane antigen operatively linked to a 5' regulatory element.--
- 77. (Amended) A therapeutic vaccine for preventing human prostate tumor growth or stimulation of prostate tumor cells in a subject, comprising administering to the subject an effective amount of claim 74, which expresses or is capable of expressing a prostate specific membrane antigen, and a pharmaceutical acceptable carrier, thereby preventing the tumor

INS
A-1